Molecular confirmation of invasive infection caused by Chaetomium globosum

Identification of the causative organism in invasive fungal infections is difficult. Accurate and reliable diagnostic methods are required in light of the increasing incidence of emerging fungal infections. We recently described a method for speciating fungi in formalin fixed, paraffin wax embedded tissue sections. DNA is extracted using a modification of the protocol for the TaKaRa DEXPAT™ kit (TaKaRa Biomedicals, Cambray Biosciences, Wokingham, UK), with additional steps using lyticate and ethanol precipitation. Amplification of the DNA is performed using panfungal primers and a method based on that described by Einsele et al. Identification to species level can be achieved by Southern hybridisation with a probe that binds Aspergillus fumigatus, A flavus, and A niger. Polymerase chain reaction products that do not hybridise with the aspergillus specific probe yielded a negative result. The DNA was purified using Wizard® PCR Prep DNA purification system (Promega, Madison, Wisconsin, USA), according to the manufacturer's instructions. The DNA was commercially sequenced (Cytonyx, Cambridge, UK), after which sequence analysis was performed with the EMBOS software package (HGMP-RC, Medical Research Council, London, UK). The sequence was identified as C globosum using a BLAST search of Genbank and EMBL nucleotide sequence databases and subsequently submitted to the EMBL database (accession number AJ817994).

The C globosum isolate had been added to the UK National Collection of Pathogenic Fungi as NCPF 7115. We subcultured this isolate then extracted, purified, and sequenced the genomic DNA. The sequence was identical to that of DNA extracted from the tissue sample, confirming the causative role of this organism in our case. With the growing population of immunocompromised patients and the broadening spectrum of antifungal agents available it is imperative that we can accurately identify the organisms causing invasive fungal infections. This case illustrates the value of molecular tools to enhance the diagnostic process.

Osseous metaplasia in a benign ovarian cyst in association with cloacal anomaly

Osseous metaplasia has been described at many sites and in association with a large number of tumours. However, previous reports of osseous metaplasia in ovarian lesions are rare, there being only three published cases, which were associated with papillary serous carcinoma, thecoma, and endometrioma. We report a case of osseous metaplasia hitherto undescribed in a benign ovarian cyst in a girl with a complex urogenital malformation. The patient was a 16 year old girl who was diagnosed with a complex cloacal anomaly at birth, requiring posterior sagittal anorectovagino-urethroplasty, followed by further lower urinary tract reconstructive procedures. At the time of surgery, non fistula and fallopian tubes were noted. She attained menarche at 14. Two years later she complained of lower abdominal pain and dysmenorrhoea. Ultrasound examination revealed a large cystic lesion in the right side of the pelvis. No calcification was seen on pelvic imaging and tumour markers were normal. Repeated aspiration did not result in longterm symptom relief and an open resection was performed. At surgery, a large multiseptated cyst was noted occupying most of the pelvis behind the augmented bladder on the right and crossing the midline, closely adherent to the right ovary and right fallopian tube. The right ovary was partially resected along with the cyst. Postoperative recovery was uneventful. Histological examination demonstrated a complex tubal cyst with chronic salpingitis, in addition to a simple follicular ovarian cyst, in the wall of which osseous metaplasia was noted (fig 1). The entire specimen was embedded and multiple sections examined, but there were no additional features present to suggest a teratoma. The pathogenesis of osseous metaplasia is unclear, but in some circumstances appears to be an unusual reaction to tissue damage and repair. It is interesting that the previously reported case associated with an endometriotic ovarian cyst also occurred in a girl with a cloacally abnormal pelvis, in a supernumerary ovary. Osseous metaplasia in a benign ovarian cyst appears to be an unusual incidental finding of unknown importance and aetiology, which is more common in...
anatomically abnormal ovarian tissue in women of reproductive age.

P Godbole, A Outram, N Sebire
Departments of Paediatric Urology and Histopathology, Great Ormond Street Hospital for Children, London WC1N 3JH, UK; prasadgodbole@binternet.com

References

Congenital bronchogenic cyst in the gastric mucosa
Bronchogenic cysts are congenital anomalies evolving from the ventral foregut between the 3rd and the 7th prenatal weeks. They are lined with cuboidal or pseudostratified ciliated epithelium and may or may not be surrounded by elastic fibres, smooth muscle, and cartilage.

Bronchogenic cysts are divided into thoracic and abdominal.1 Abdominal bronchogenic cysts are rare, particularly those located exclusively within the confines of the gastric wall. Despite the fact that ‘Gensler and colleagues’ described the first case nearly 50 years ago, only two additional cases have been reported.2 Recently, we identified a new case of bronchogenic cyst in the gastric mucosa. The purpose of this letter is to draw attention to an important differential diagnosis between gastric congenital intramucosal cysts and acquired intramucosal cysts also lined with ciliated cells.3

A 26 year old Swedish man presented because of periodic epigastric pain. The pain began 18 months previously and was periodically treated with proton pump inhibitors. Palpation resulted in epigastric pain. Oesophageal manometry and pH were normal. Gastroscopy showed mild oesophagitis and normal gastric mucosa. Pinch biopsies revealed grade 1 oesophagitis and normal gastric mucosa without Helicobacter pylori infection. However, an intramucosal cyst was found in one of the biopsies from the corpus. That cyst was lined with pseudostratified epithelium built from cuboidal cells (fig 1), some of them vacuolated. Cartilaginous tissue was not found but a lymphatic follicle was present in the lamina propria. The adjacent mucosa of the fundus was normal. The cells lining the luminal aspect of the cyst had densely packed cilia (fig 1). Each cillum was approximately 6 μm long and stained positively for tubulin B (fig 2). Staining with periodic acid Schiff diastase revealed only one positive clear cell. The aforementioned vacuolated cells were periodic acid Schiff negative. Staining for Ki67 (clone MIB1) showed no signs of epithelial proliferation. The patient received omeprazole medication and the symptoms disappeared.

The histological lining of this bronchogenic cyst differs from other reported intramucosal gastric cysts also lacking cartilage; namely: foveolar, fundic pyloric, intestinal metaplasia, and ciliated metaplastic cysts.4 Cysts with ciliated metaplasia are usually located in the antrum and they are lined with a single row of gastric seromucinous cuboidal cells or with intestinal metaplastic goblet cells that have irregular cilia. Cysts with ciliated metaplasia evolve as a result of environmental factors, particularly in Asian patients harbouring a gastric carcinoma of the intestinal type.5 Gastric bronchogenic cysts are rare; a similar type of cyst has not been found in two large series comprising 1675 gastric biopsies6 and 3400 resected stomachs7 from patients dwelling in disparate geographical regions.

In conclusion, congenital bronchogenic cysts should be differentiated from acquired ciliated gastric cysts evolving as a consequence of environmental factors.3

CA Rubio, A Orrego
Department of Pathology, Gastrointestinal and Liver Pathology Research Laboratory, Karolinska Institute, 76 Stockholm, Sweden; carlos.rubio@karolinska.se

R Willén
Department of Pathology, Uppsala University Academic Hospital, 75185 Uppsala, Sweden

Figure 2 Gastric intramucosal bronchogenic cyst showing ciliated structures expressing tubulin B (immunohistochemical staining for tubulin B: original magnification, ×25).

Figure 1 Gastric intramucosal bronchogenic cyst with ciliated pseudostratified epithelium (haematoxylin and eosin stain; original magnification, ×50).

Expression of HIF-1α in human tumours
We have read with interest the recent paper by Jubb et al on the expression of hypoxia inducible factor 1α (HIF-1α) in human tumours.8 We note that they report only 5% of ductal adenocarcinomas to be HIF-1α positive. This proportion is unusually low compared with our own data and those of other workers. In our various studies, the proportion of HIF-1α positive breast cancers varies from 44% to 70%. In other groups, these percentages varied from 56% to 76%.9,10 We believe that this discrepancy may be caused by the use of tissue microarrays. In breast cancer, HIF-1α often shows pronounced intratumour heterogeneity because of focal perinecrotic staining, which is clinically highly relevant. Even patients with only 5% of cells overexpressing VEGF-D and HIF-1α in breast cancer
In a recent paper in the Journal of Clinical Pathology, Currie et al used immunohistochemistry on tissue microarrays to assess the expression of the hypoxia inducible factor 1α (HIF-1α) protein in breast cancer.11 As we point out in a letter to this issue of the journal,12 tissue microarrays are not very suitable for HIF-1α immunohistochemistry because focal perinecrotic HIF-1α staining is easily missed in the small tissue samples forming a tissue microarray. However, this perinecrotic type of HIF-1α expression is relevant in breast cancer.11

Furthermore, the authors assessed HIF-1α expression considering both the intensity and extent of nuclear and cytoplasmic reactivity. To our knowledge, there are no data supporting a functional role for cytoplasmic HIF-1α expression in breast cancer. Therefore, previous studies have only considered nuclear staining. Lastly, the authors describe how they arrive at a score in a particular case after considering “both the intensity and extent of nuclear and cytoplasmic reactivity”, and also the threshold used in statistical analysis is not provided. Further enlightenment on these matters would help us to appreciate the value of their findings. Perhaps, the lack of prognostic value of vascular endothelial growth factor D, which induces lymphangiogenesis, can be explained by the absence of lymphangiogenesis in invasive breast cancer.13

P J van Diest, M M Vleugel, P van der Groep, E van der Wall
Departments of Pathology and Medical Oncology, UMCG, Utrecht, 3508 GA, The Netherlands; p.j.vandiest@lab.azu.nl

References
HIF-1α has a much worse prognosis. Thus, tissue arrays probably underestimate the true frequency of HIF-1α overexpression in breast cancer. Hence, data from studies on HIF-1α derived from tissue arrays are probably less reliable with regard to associations between HIF-1α and other biomarkers and prognosis for invasive breast cancer. Therefore, we believed that conventional tumour sections are superior for the assessment of HIF-1α overexpression in this type of cancer. For other cancers with a more diffuse type of staining this may be different.

P J van Diest
Department of Pathology, University Medical Centre Utrecht, PO Box 85500 Utrecht, The Netherlands; p.j.vandiest@hku.uva.nl

M M Vleugel
Department of Pathology, VU University Medical Centre, 1007 MB Amsterdam, The Netherlands

E van der Wall
Department of Pathology, University Medical Centre Utrecht

References

Authors’ reply
We thank Professor van Diest and colleagues for their letter raising some interesting issues about hypoxia inducible factor 1α (HIF-1α) in breast cancer. Our study examined vascular endothelial growth factor D (VEGF-D) expression in breast cancer and correlated expression with clinicopathological variables, with an emphasis on hypoxia markers. Van Diest et al suggest that tissue microarrays (TMAs) are unsuitable for the analysis of HIF-1α because they may miss a particular pattern of HIF-1α staining that has prognostic relevance. However, the clinical impact of these patterns is unclear because in their study HIF-1α was highly associated with necrosis and grade and the survival analysis was not multivariate. Nevertheless, we agree that we identified fewer HIF-1α positive tumours than van Diest et al, who reported 75%, 54%, and 44% positivity in three studies using a 1% cutoff value, or 34% in another study when using a 5% cutoff value. However, although van Diest et al suggest that others have found a similar range of HIF-1α positivity (56% and 76%), appraisal of the published data shows that only strong HIF-1α staining is used, then these studies show 23% HIF-1α positivity. Moreover, Zhong et al using whole tissue sections of breast tumours reported strong HIF-1α expression in only 12%. We used a semiquantitative score of negative, weak staining, or strong staining and considered strong staining as positive (the proportion of cells was also noted: 0, 0%; 1, 1–10%; 2, 11–50%; 3, 51–80%; and 4, 81–100%), but in practice when strong staining was present all the tumour cells were positive. If we re-stratify our cases using the criteria of van Diest and colleagues—nuclei that are “completely and darkly stained” and >1% cutoff points—we have a positivity rate of 78%, which is within the range reported by van Diest et al. Indeed, because each core within a TMA can hold up to 1000 cells, we may be analysing similar amounts of tumour, but the methodology in the van Diest group’s papers with regard to the number of cells, the ranges, medians, etc is unclear, so it is not possible to assess this. Thus, we think that although we may miss some HIF-1α positive cases, it is probably only a small proportion, and may be compensated for by the absence of variability in staining that is common in studying large series by whole tissue sections. Furthermore, because we specifically wish to analyse the relation between molecular markers in the same region of the tumour (in the individual core/exemplar), we view the use of TMAs as an advantage.

Van Diest and colleagues also raise the issue of the subcellular localisation of HIF-1α. Cytoplasmic expression of HIF-1α is well recognised. To ignore it appears to us premature just because it does not fit in with current models. Many so called cytoplasmic or nuclear only proteins have now been shown to shuttle to and fro between the two compartments. Indeed, it has been shown that a nuclear location is not required for HIF-1α stabilisation and that HIF-1α undergoes oxygen dependent posttranslational degradation in both the nucleus and the cytoplasm.

Lastly, van Diest et al suggest that the lack of an association between VEGF-D and prognosis may be explained by the absence of lymphangiogenesis in breast cancer. The notion that VEGF-D enhances lymphangiogenesis and thereby influences nodal status and prognosis is somewhat one dimensional because VEGF-D has other functions in addition to lymphangiogenesis, including lymphatic growth, lymphatic maintenance, and angiogenesis.

Thus, we think that the lack of an association is more likely the result of several factors leading to nodal metastasis, including VEGF-C, with differences in processing resulting in changes in receptor affinity. Furthermore, it is also likely that a combination of factors rather than a single factor will be clinically useful."

M J Currie, V Hanrahan, S P Gunningsmith, H R Morriss, C Frampton, C Han, B A Robinson, S B Fox
Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK; stephen.fox@ndcls.ox.ac.uk

References


Full details of events to be included should be sent to Maggie Butler, Technical Editor JCP, The Cadars, 36 Queen Street, Castle Hedingham, Essex CO9 3HA, UK; email: maggie.butler@bepoworld.com

Further details:
Ms A Davies, Department of Histopathology, First Floor Clinical Sciences Building, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WJ, UK.
Tel (+44) (0)161 276 8725; Fax (+44) (0)161 276 6348; e-mail amanda.davies@cmcc.nhs.uk

Association of Clinical Pathologists’ National Scientific Meeting
16–17 June 2005, Royal College of Physicians, London, UK
Further details: ACP Central Office, 189 Dyke Road, Hove BN3 1LT, UK. (Tel (+44) (0)1273 775700; e-mail info@pathologists.org.uk)

Practical Pulmonary Pathology
26–29 July 2005, Royal Brompton Hospital, London, UK
Further details: Professor B Corrin, Brompton Hospital, London SW3 6NP, UK. (Fax (+44) (0)20 7 351 8293; e-mail b.corrin@ic.ac.uk)

www.jclinpath.com